Posted by Michael Wonder on 29 Aug 2019
U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta
29 August 2019 - The U.S. Food and Drug Administration on Thursday granted Mylan tentative approval for its generic version of Eli Lilly and Co’s lung cancer drug Alimta.
A tentative approval generally signals that the FDA has signed off on the company’s marketing application, but that it cannot sell the medicine until the U.S. patents have expired.
Lilly stands to lose U.S. patent protection on the chemotherapy drug, known generically as pemetrexed, in 2022.
